youtube_live
Q2 2027 earnings • released • EPS beat +58.88% • Revenue beat +716.75%
See resultschevron_right
ROIV:NASDAQ
Roivant Sciences Ltd
$41.85
arrow_upward
+1.60%(+0.66) 1D
$41.32
arrow_downward
-1.27% (-0.53)bedtimeAfter hours
Closed: Nov 11, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ROIV...
Open
$41.47
High
$42.24
Low
$40.86
Mkt. cap
30.23B
Avg. vol.
7.19M
Volume
0.00
52-wk high
$42.50
52-wk low
$19.96
EPS
-$0.39
Beta
1.23
Shares outstanding
724.56M
No. of employees
721
Open
$41.47
High
$42.24
Low
$40.86
Mkt. cap
30.23B
Avg. vol.
7.19M
Volume
0.00
52-wk high
$42.50
52-wk low
$19.96
EPS
-$0.39
Beta
1.23
Shares outstanding
724.56M
No. of employees
721
News stories
From web sources and news partners
Yahoo Finance
·
11 hours ago
Roivant Sciences Ltd. (ROIV) Stock Forecasts
Benzinga
·
1 day ago
Nvidia To $300? Here Are 10 Top Analyst Forecasts For Tuesday
GuruFocus
·
1 day ago
ROIV Maintained by HC Wainwright & Co. -- Price Target Raised to $48
TOKENPOST
·
1 day ago
Roivant Posts $35.121 Million in Revenue for Its Second Quarter
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd
CEOMatt Gline
Employees721
FoundedApr 7, 2014
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteroivant.com
Analyst ratings
Based on 12 analysts giving stock ratings to ROIV in the past 3 months
Strong buy
Buy
10
Hold
2
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ROIV in the last 3 months.
Highest
Current $41.85
$62.00 (+48.15%)
Average
$49.20 (+17.56%)
Lowest
$40.00 (-4.42%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Brian Cheng J.P. Morgan | Buy | Maintained | - | - | 11/09/2026 |
Samantha Semenkow Citi | Buy | Maintained | $56.00 | +33.8% | 11/09/2026 |
Chi Meng Fong Bank of America Securities | Hold | Reiterated | $42.00 | +0.4% | 11/09/2026 |
Douglas Tsao H.C. Wainwright | Buy | Maintained | $48.00 | +14.7% | 11/10/2026 |
Unknown Analyst Leerink Partners | Buy | Maintained | $54.00 | +29% | 11/02/2026 |
Yaron Werber TD Cowen | Buy | Maintained | $62.00 | +48.1% | 10/21/2026 |
Andy Chen Wolfe Research | Hold | Downgraded | - | - | 10/12/2026 |
Eve Burstein Bernstein | Buy | Maintained | $41.00 | -2% | 09/25/2026 |
Alex Thompson CFA Stifel Nicolaus | Buy | Initiated | $51.00 | +21.9% | 09/17/2026 |
Yatin Suneja Guggenheim | Buy | Reiterated | $46.00 | +9.9% | 09/08/2026 |
Dennis Ding Jefferies | Buy | Maintained | $52.00 | +24.3% | 09/08/2026 |
Yasmeen Rahimi Piper Sandler | Buy | Maintained | $40.00 | -4.4% | 08/28/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $42.00 | +0.4% | 08/18/2026 |
Allison Bratzel Piper Sandler | Buy | Maintained | $40.00 | -4.4% | 04/16/2026 |
Corinne Johnson Goldman Sachs | Buy | Maintained | $41.00 | -2% | 04/15/2026 |
William Pickering Bernstein | Buy | Initiated | $35.00 | -16.4% | 03/20/2026 |
Last report
Nov 9, 2026
Fiscal period
Q2 2027
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.18 / -$0.45
+58.88%beat
arrow_upward
Revenue / Est. (USD)
35.12M / 4.30M
+716.75%beat
arrow_upward
Fiscal Q2 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.57M | 2.00M | 2.52M | 1.44M |
Cost of goods sold | 164.18M | 166.08M | 199.26M | 202.30M |
Cost of revenue | 164.18M | 166.08M | 199.26M | 202.30M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 129.52M | 175.05M | 155.97M | 165.53M |
Operating expense | 129.52M | 175.05M | 155.97M | 165.53M |
Total operating expenses | 293.70M | 341.13M | 355.23M | 367.83M |
Operating income | -292.13M | -339.14M | -352.71M | -366.38M |
Other non operating income | -26.65M | -16.07M | 7.47M | -2.93M |
EBT including unusual items | -159.04M | -290.37M | 454.10M | -294.56M |
EBT excluding unusual items | -273.44M | -311.94M | -298.96M | -331.59M |
Income tax expense | 7.00M | 23.33M | 98.35M | -3.96M |
Effective tax rate | -4.40% | -8.04% | 21.66% | 1.34% |
Other operating expenses | - | - | - | - |
Net income | -113.52M | -265.89M | 302.99M | -189.84M |
Net profit margin | -7,225.91% | -13,301.20% | 12,023.57% | -13,164.84% |
Earnings per share | -0.28 | -0.24 | -0.32 | -0.34 |
Interest and investment income | 45.34M | 43.27M | 41.18M | 36.92M |
Interest expense | - | - | - | - |
Net interest expenses | 45.34M | 43.27M | 41.18M | 36.92M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -291.21M | -338.44M | -352.07M | -365.78M |
Gain or loss from assets sale | - | - | -11.03M | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events